Fluid monitor utilises AI to identify, localise and quantify retinal fluid

Article

Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.

At this year’s EURETINA in Hamburg, Germany, there were several engaging presentations during the Symposium Session that took place on the Friday, 2nd September on the important topic of artificial intelligence (AI) tools for fluid monitoring in neovascular age-related macular degeneration (nAMD).

Towards the end of the Symposium Session, Stela Vujosevic, head of the Medical Retina Service at the University Hospital, “Maggiore della Carità”, Novara, Italy, provided attendees with some practical guidance on handling the RetInSight Fluid Monitor, a Class IIa medical device that can be used to help support clinical decisions in the monitoring of patients with nAMD in Europe.

The fluid monitor is designed to identify, localise and quantify retinal fluid in routine OCT images. It assigns a label to each OCT pixel, denoting the fluid type as IRF, SRF or PED, and provides its location within the central 1-mm and 6-mm macular area. Fluid measurements are provided in nanolitres.

According to Dr Vujosevic, it is important to distinguish between the specific fluid compartments due to the differences in the impact on visual function and the dynamics of fluid resolution whilst patients are receiving different treatment regimens. She explained that the measurements and readouts of fluid activity enable ophthalmologists to monitor disease progression or response to treatment. The monitor is intended to be compatible with all leading OCT systems.

Dr Vujosevic went onto discuss that the AI-based software can be deployed by the OCT operator under the supervision of an eyecare specialist in the clinic environment, producing a concise and highly accurate real-time report containing patient results whilst the patient is on site. Benefits to patients include shorter waiting times for appointments, less inconvenience and lower cost associated with travelling and absence from work resulting from over-treatment, as well as a lowered risk of vision loss caused by under-treatment.

Meanwhile, eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.